In vitro inhibition and induction of human liver cytochrome P450 enzymes by gentiopicroside: Potent effect on CYP2A6

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 4, 2013, Pages 339-344

  Deng, Yating ^a   Wang, Lu ^b   Yang, Yong ^c   Sun, Wenji ^d   Xie, Renming ^d   Liu, Xueying ^a   Wang, Qingwei ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b SHAANXI UNIVERSITY OF CHINESE MEDICINE   (China)

^c Shaanxi Polytechnic Institute   (China)

^d NORTHWEST UNIVERSITY   (China)

Author keywords

Gentiopicroside; In vitro; Induction; Inhibition; P450s

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GENTIOPICRIN; OMEPRAZOLE; PHENOBARBITAL; RIFAMPICIN;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER; LIVER CELL; LIVER MICROSOME; LIVER PROTECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ARYL HYDROCARBON HYDROXYLASES; CELLS, CULTURED; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; IRIDOID GLUCOSIDES; MICROSOMES, LIVER;

EID: 84883170335     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-090     Document Type: Article

References (16)

1. Tan, R. X. and Kong, L. D.: Secoiridoids from Gentiana siphonantha. Phytochemistry, 46: 1035-1038 (1997).
2. Li, Y. Q., Zhao, D. H. and Pan, B. R.: Effect of gentiopicroside on liver injury of rats. J. Fourth Mil. Med. Univ., 22: 1645-1649 (2001).
3. Rojas, A., Bah, M., Rojas, J. I. and Gutiérrez, D. M.: Smooth muscle relaxing activity of gentiopicroside isolated from Gentiana spathacea. Planta Med., 66: 765-767 (2000).
4. Wang, C. H., Wang, Z. T., Bligh, S. W., White, K. N. and White, C. J.: Pharmacokinetics and tissue distribution of gentiopicroside following oral and intravenous administration in mice. Eur. J. Drug Metab. Pharmacokinet., 29: 199-203 (2004).
5. el-Sedawy, A. I., Hattori, M., Kobashi, K. and Namba, T.: Metabolism of gentiopicroside (gentiopicrin) by human intestinal bacteria. Chem. Pharm. Bull. (Tokyo), 37: 2435-2437 (1989).
6. Paolini, M., Pozzetti, L., Montagnani, M., Potenza, G., Sabatini, L., Antelli, A., Cantelli-Forti, G. and Roda, A.: Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities. Hepatology, 36: 305-314 (2002).
7. Jang, S. I., Kim, H. J., Hwang, K. M., Jekal, S. J., Pae, H. O., Choi, B. M., Yun, Y. G., Kwon, T. O., Chung, H. T. and Kim, Y. C.: Hepatoprotective effect of baicalin, a major flavone from Scutellaria radix, on acetaminophen-induced liver injury in mice. Immunopharmacol. Immunotoxicol., 25: 585-594 (2003).
8. Lee, H. I., Seo, K. O., Yun, K. W., Kim, M. J. and Lee, M. K.: Comparative study of the hepatoprotective efficacy of Artemisia iwayomogi and Artemisia capillaris on ethanol-administered mice. J. Food Sci., 76: T207-T211 (2011).
9. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory/ Information/Guidances/ucm292362.pdf
10. Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G. and Ni, L.: The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos., 31: 815-832 (2003).
11. Huang, S. M., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S., Temple, R., Abraham, S., Habet, S. A., Baweja, R. K. and Burckart, G. J.: New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol., 48: 662-670 (2008).
12. Ogilvie, B. W., Usuki, E., Yerino, P. and Parkinson, A.: In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450, in Drug-Drug Interactions. In Rodrigues, A. D. (ed.): Drugs and the Pharmaceutical Sciences, 2nd ed., New York, Informa Healthcare, 2008, pp. 231-358.
13. Li, A. P., Roque, M. A., Beck, D. J. and Kaminski, D. L.: Isolation and culturing of hepatocytes from human livers. Methods Cell Sci., 14: 139-145 (1992).
14. Yan, D., Yang, Y., Uchida, S., Misaka, S., Luo, J., Takeuchi, K., Inui, N., Yamada, S., Ohashi, K. and Watanabe, H.: Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. Naunyn Schmiedebergs Arch. Pharmacol., 377: 629-636 (2008).
15. Yu, C., Chai, X., Yu, L., Chen, S. and Zeng, S.: Identification of novel pregnane X receptor activators from traditional Chinese medicines. J. Ethnopharmacol., 136: 137-143 (2011).
16. Fan, L., Wang, J. C., Jiang, F., Tan, Z. R., Chen, Y., Li, Q., Zhang, W., Wang, G., Lei, H. P., Hu, D. L., Wang, D. and Zhou, H. H.: Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur. J. Clin. Pharmacol., 65: 403-409 (2009).